ZCCHC16 Inhibitors
ZCCHC16 Inhibitors function through a variety of mechanisms to curtail the activity of ZCCHC16, a protein that may be involved in RNA binding and potentially other cellular processes. These inhibitors target several key signaling pathways, such as the PI3K/AKT/mTOR pathway, a crucial cascade in regulating protein synthesis and cell growth. By inhibiting PI3K with specific compounds, the downstream signaling necessary for the optimal activity of ZCCHC16 is disrupted, leading to a reduction in the protein's functional activity. Similarly, compounds that inhibit mTOR directly affect protein synthesis pathways, which could be critical for ZCCHC16's role in the cellular milieu. Furthermore, the inhibition of kinases that phosphorylate various proteins can also lead to a decrease in ZCCHC16 activity if it relies on phosphorylation for its function. The broad kinase inhibition by certain compounds could, therefore, suppress necessary phosphorylation events that ZCCHC16 may require for its activation or stability.
Moreover, other inhibitors target the MAPK/ERK and p38 MAPK pathways, essential for various cellular responses, including gene expression, cell division, and survival. If ZCCHC16 operates downstream of these pathways, inhibiting MEK or p38 MAPK would indirectly diminish ZCCHC16's activity by limiting the signaling cues that ZCCHC16 might depend on. Additionally, the cytoskeletal dynamics within the cell are influenced by compounds that inhibit ROCK, which could affect the structural context in which ZCCHC16 functions. Inhibition of JNK signaling could also result in reduced ZCCHC16 activity if it is modulated by JNK-mediated processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
As a potent kinase inhibitor, Staurosporine inhibits a broad spectrum of kinases which could lead to suppression of kinase-mediated phosphorylation processes ZCCHC16 may be involved in. If ZCCHC16 function is regulated by phosphorylation, the use of Staurosporine would result in the inhibition of ZCCHC16’s functional activity by preventing its necessary phosphorylation. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671, a specific inhibitor of the p70 S6 kinase, would inhibit the downstream signaling of the PI3K/AKT/mTOR pathway. Given that this pathway is crucial for protein synthesis and ZCCHC16 has a role in RNA binding, the inhibition of this pathway could lead to decreased functional activity of ZCCHC16 by limiting its interaction with its RNA targets. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor, obstructing the PI3K/AKT pathway. If ZCCHC16 is implicated in cellular processes downstream of PI3K signaling, this inhibition could lead to a reduction in ZCCHC16 activity indirectly by altering the signaling context in which ZCCHC16 exerts its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 acts as a MEK inhibitor, thereby disrupting the MAPK/ERK pathway. If ZCCHC16 functions are modulated by MAPK/ERK signaling, U0126 would lead to an indirect inhibition of ZCCHC16 by impeding the pathway necessary for its optimal activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, which would lead to a decrease in actin cytoskeleton reorganization. Since ZCCHC16 is a zinc-finger protein that might interact with other proteins related to cytoskeleton dynamics, inhibition of ROCK could therefore indirectly diminish ZCCHC16's role in cellular structural maintenance or modification. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941 is a pan-class I PI3K inhibitor which would suppress the PI3K/AKT/mTOR signaling cascade. If ZCCHC16 activities are connected to or dependent on this pathway, then GDC-0941 would lead to the indirect inhibition of ZCCHC16 by destabilizing the signaling milieu essential for ZCCHC16's functional mechanisms. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an inhibitor of MEK, which in turn prevents activation of ERK. If ZCCHC16 requires ERK signaling for its activity, inhibition of this pathway by PD 98059 would lead to decreased functional activity of ZCCHC16. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK signaling, SB 203580 could indirectly reduce ZCCHC16 activity if ZCCHC16's functional mechanisms are modulated by or dependent on the p38 MAPK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By blocking PI3K signaling, it could reduce the functional activity of ZCCHC16 indirectly if ZCCHC16 is involved in pathways or processes downstream of PI3K activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, which can suppress mTORC1 signaling. By inhibiting mTORC1, Rapamycin would disrupt protein synthesis and cell growth pathways that may be necessary for ZCCHC16 activity, thus leading to an indirect inhibition of ZCCHC16. | ||||||